Sun Yu-Qian, Chang Ying-Jun, Huang Xiao-Jun
a Peking University People's Hospital , Peking University Institute of Hematology , Beijing , China.
b Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation for the Treatment of Hematological Diseases , Beijing , P.R. China.
Expert Rev Hematol. 2018 Apr;11(4):273-284. doi: 10.1080/17474086.2018.1447379. Epub 2018 Mar 6.
Haploidentical stem cell transplantation (Haplo-SCT) is currently a suitable alternative worldwide for patients with hematological diseases, who lack human leukocyte antigen (HLA)-matched siblings or unrelated donors. Areas covered: This review summarizes the advancements in Haplo-SCT in recent years, primarily focusing on the global trends of haploidentical allograft, the comparison of outcomes between Haplo-SCT and other transplantation modalities, strategies for improving clinical outcomes, including donor selection, hematopoietic reconstitution promotion, and graft-versus-host disease, and relapse prevention/management, as well as the expanded indications of Haplo-SCT, such as severe aplastic anemia, myeloma and lymphoma. Expert commentary: Haploidentical allografts, including granulocyte colony-stimulating factor-based protocol and a post-transplant cyclophosphamide-based protocol, have been the mainstream strategy for Haplo-SCT. However, there are many unanswered questions in this field.
单倍体相合干细胞移植（Haplo-SCT）目前是全球范围内对于缺乏人类白细胞抗原（HLA）匹配同胞或无关供者的血液系统疾病患者的一种合适替代方案。涵盖领域：本综述总结了近年来Haplo-SCT的进展，主要关注单倍体相合同种异体移植的全球趋势、Haplo-SCT与其他移植方式的结局比较、改善临床结局的策略，包括供者选择、促进造血重建和移植物抗宿主病以及预防/管理复发，以及Haplo-SCT的扩展适应证，如重型再生障碍性贫血、骨髓瘤和淋巴瘤。专家评论：包括基于粒细胞集落刺激因子的方案和基于移植后环磷酰胺的方案在内的单倍体相合同种异体移植一直是Haplo-SCT的主流策略。然而，该领域仍有许多未解决的问题。
